Efficacy and safety of disitamab vedotin in treatment of advanced gastric cancer based on real-world - Scorecard - MDSpire

Efficacy and safety of disitamab vedotin in treatment of advanced gastric cancer based on real-world

  • By

  • Pan Cheng

  • Jianjuan Ge

  • Shuangjia Huang

  • Dongzan Yang

  • Shining Xie

  • Bowen Wang

  • Zhaoshi Bai

  • Jichen He

  • Xiaolin Liu

  • May 20, 2026

  • 0 min

Share

Clinical Scorecard: Real-World Assessment of Disitamab Vedotin's Efficacy and Safety in Advanced Gastric Cancer Treatment

At a Glance

CategoryDetail
Condition
Key MechanismsDisitamab vedotin (RC48) targets HER2 and delivers cytotoxic MMAE to tumor cells, inducing apoptosis. The VC linker is cleaved in lysosomes, releasing MMAE.
Target Population
Care Setting

Key Highlights

  • DCR_comparison

Guideline-Based Recommendations

Diagnosis

    Management

      Monitoring & Follow-up

      • M
      • o
      • n
      • i
      • t
      • o
      • r
      • f
      • o
      • r
      • a
      • d
      • v
      • e
      • r
      • s
      • e
      • d
      • r
      • u
      • g
      • r
      • e
      • a
      • c
      • t
      • i
      • o
      • n
      • s
      • ,
      • p
      • r
      • o
      • g
      • r
      • e
      • s
      • s
      • i
      • o
      • n
      • -
      • f
      • r
      • e
      • e
      • s
      • u
      • r
      • v
      • i
      • v
      • a
      • l
      • ,
      • a
      • n
      • d
      • o
      • v
      • e
      • r
      • a
      • l
      • l
      • s
      • u
      • r
      • v
      • i
      • v
      • a
      • l
      • r
      • a
      • t
      • e
      • s
      • .

      Risks

        Patient & Prescribing Data

        Clinical Best Practices

        • criteria

        Related Resources & Content

        Original Source(s)

        Efficacy and safety of disitamab vedotin in treatment of advanced gastric cancer based on real-world

        • by Pan Cheng, Jianjuan Ge, Shuangjia Huang, Dongzan Yang, Shining Xie, Bowen Wang, Zhaoshi Bai, Jichen He, Xiaolin Liu

        • May 20, 2026

        Related Content

        Financial Hardship and Nonadherence to Lifestyle and Surveillance in Childhood Cancer Survivors

        Is full adherence mandatory? Real-world outcomes of completing perioperative chemoimmunotherapy in resectable non-small cell lung cancer

        Characteristics and risk factors of immune-related adverse events in patients receiving immune checkpoint inhibitor combination therapy